#2 Limited access of CAR-T cells to solid tumours

So far it has proven a challenge to deliver clinically effective doses of CAR-T cells to solid tumours or resection (after surgery) sites.

One of the issues to overcome is that CAR-T cells often move away from the tumour/resection site before they have had a chance to work.

2018-09-10T11:56:01+09:30